- New data advances understanding of new approaches to treating Alzheimer's disease
- Research on disease progression could help inform future clinical trials
CAMBRIDGE, Mass., March 4, 2024 (GLOBE NEWSWIRE) — Biogen, Inc. (Nasdaq: BIIB) has announced that the upcoming International Conference on Alzheimer's and Parkinson's Disease (AD/ PD™ 2024) will be held in March. It will be held virtually from the 5th to the 9th in Lisbon, Portugal. Presentations will include new data on an oral tau aggregation inhibitor (BIIB113) and a presentation providing insight into the mechanisms underlying Alzheimer's disease.
“These data reflect our approach to exploring multiple pathologies and modalities of Alzheimer's disease to create a leading portfolio that can change the course of Alzheimer's treatment,” Biogen executives said. said Priya Singhal, MD, MPH, vice president and head of development. “Our continued investment in Alzheimer's research strengthens our commitment to pushing the boundaries of innovation and making a real difference in the lives of people living with this complex disease.”
Biogen presentation provides new data on brain target engagement and safety profile in healthy volunteers of an oral small molecule O-GlcNAcase (OGA) enzyme inhibitor (BIIB113) aimed at reducing tau aggregation will be done. In addition to BIIB113, Biogen is investigating the potential for tau reduction in AD using an investigational antisense oligonucleotide targeting the microtubule-associated protein tau (MAPT) gene (BIIB080). Other presentations will discuss the long-term efficacy of lecanemab and the presence of alpha-synuclein pathology in Alzheimer's disease, which may inform future research on lecanemab's role in the clinical progression of Alzheimer's disease. .
Key presentations include:
- Oral Presentation: Results of the first in-human, randomized, blinded, placebo-controlled, single and multiple escalating dose study of BIIB113 in healthy volunteers. Friday, March 8, 9:55-10:10 a.m. GMT / 4:55-5:10 a.m. ET.
- Oral presentation: Distribution of alpha-synuclein copathology in MCI, mild Alzheimer's disease, and progressive supranuclear palsy clinical trial cohorts. Friday, March 8, 6:55-7:10pm GMT / 1:55-2:10pm ET.
- Oral presentation: Treatment with lecanemab disrupts tau accumulation across brain regions in early Alzheimer's disease. Provided by Eisai. Thursday, March 7th, 1:50pm – 2:05pm GMT / 8:50am – 9:05am EST.
- Oral presentation: Lecanemab for early Alzheimer's disease treatment. Clarity AD has extended effectiveness. Provided by Eisai. Saturday, March 9th, 9:10am-9:25am GMT / 4:10am-4:25am ET.
- On-demand oral presentation: Neurodynamic Quantitative Systems Pharmacology (QSP) Model of Alzheimer's Disease Incorporating Amyloid and Tau Pathophysiology; online.
- Poster presentation: Relationship between minimum inclusion criteria and subsequent cognitive decline; P#0250, Wednesday, March 6, 9am GMT.
- E Poster Presentation: Occupancy of BIIB113, an inhibitor of the enzyme O-GlcNAcase (OGA), in the human brain.
BIIB080 is licensed from Ionis.
About Biogen
Founded in 1978, Biogen is a leading biotechnology company pioneering innovative science that delivers new medicines that transform the lives of patients and create value for our shareholders and communities. We apply our deep understanding of human biology and leverage a variety of modalities to advance first-in-class treatments and treatments that deliver superior results. Our approach is to take bold risks while balancing investment returns to achieve long-term growth.
We periodically post information we believe is important to investors on our website (www.biogen.com). Follow us on social media including Twitter, LinkedIn, Facebook, and YouTube.
Biogen Safe Harbor
This news release contains forward-looking statements regarding the potential clinical efficacy of resenamab, BIIB113 and BIIB080. Potential benefits, safety, and efficacy of resenamab, BIIB113, and BIIB080. Clinical development program for resenamab, BIIB113 and BIIB080. Identifying and treating Alzheimer's and Parkinson's disease. Research and development program for ALS treatment. the potential of our commercial business and pipeline programs, including resenamab, BIIB113 and BIIB080; risks and uncertainties associated with the development and commercialization of pharmaceutical products; These forward-looking statements include words such as “aim,” “anticipate,” “believe,” “may,” “estimate,” “expect,” “predict,” “intend,” “anticipate,” “anticipate,” “believe,” “may,” “estimate,” “anticipate,” “predict,” “intend,” “anticipate,” “anticipate,” “believe,” “may,” “estimate,” “anticipate,” “project,” “intend,” “anticipate,” “anticipate,” “believe,” “may,” “estimate,” It may be accompanied by words such as “may” and “plan.” , “could,” “potential,” “will,” “would,” and other words and terms of similar meaning. The development and commercialization of pharmaceutical products involves high risks, and only a small number of research and development programs lead to commercialization of products. Results from early-stage clinical trials may not be indicative of the complete results or results of later-stage or larger-scale clinical trials and do not guarantee regulatory approval. Do not place undue reliance on our forward-looking statements.
These statements include, but are not limited to, uncertainties regarding the successful development and commercialization potential of resenamab, BIIB113 and BIIB080, which could cause actual results to differ materially from those reflected in such statements; involve risks and uncertainties. the risk that we may not be able to fully enroll in clinical trials or that enrollment will take longer than expected; Unanticipated concerns may arise from additional data, analyzes and results obtained during clinical trials. Regulatory authorities may require additional information or further studies, which could result in failure, denial, or delay in approval of our drug candidates, including BIIB113 and his BIIB080. Occurrence of adverse safety events. risk of unanticipated hurdles, costs and delays; failure to protect and enforce our data, intellectual property and other proprietary rights, and uncertainties related to intellectual property claims and contests; Product liability claims. Operating Results and Financial Condition. The forward-looking statements above identify many, but not all, of the factors that could cause actual results to differ from our expectations. In addition to this cautionary statement, investors should consider the risk factors identified in the Company's most recent annual or quarterly reports and other reports filed by the Company with the Securities and Exchange Commission. . These statements speak only as of the date of this news release.
The Company undertakes no obligation to publicly update any forward-looking statements.